NervGen Pharma Corp.

NervGen Pharma Corp. is a clinical-stage biopharmaceutical company dedicated to developing first-in-class neuroreparative therapeutics. The company's mission is to enable the nervous system to repair itself following damage, aiming to transform the lives of individuals living with neurotraumatic and neurologic conditions. NervGen Pharma's corporate office is located in Vancouver, British Columbia, Canada.

The company's lead therapeutic candidate is NVG-291, a subcutaneously administered neuroreparative peptide. NVG-291 is designed to target the inhibitory chondroitin sulfate proteoglycan (CSPG)-protein tyrosine phosphatase sigma (PTPσ) pathway, thereby promoting nervous system repair. It is currently being evaluated in Phase 1b/2a clinical trials for spinal cord injury (SCI) and has received Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency for SCI. NervGen is also advancing NVG-300, a next-generation candidate, through preclinical evaluation for conditions such as ischemic stroke, amyotrophic lateral sclerosis (ALS), and SCI.

In recent developments, NervGen Pharma successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), securing alignment for RESTORE, a Phase 3 registrational study of NVG-291 for chronic tetraplegia, with initiation anticipated in mid-2026. The leadership team includes Adam Rogers, MD, who was appointed President and CEO in February 2026, and Keith Vendola, MD, MBA, who became Chief Financial Officer in April 2026.